Cefepime Use Linked to Elevated Death Risk in Large Trial Review
A systematic review and meta-analysis of 110 randomized trials involving over 22,000 patients found a 94.4% probability that cefepime is associated with increased all-cause mortality compared with other beta-lactams. The absolute difference was small (6.6% vs 6.2%), and the authors caution that the signal may reflect dosing issues rather than an inherent drug problem. They emphasize that the findings do not imply cefepime should be abandoned, but rather prompt careful dosing and monitoring.
The analysis, appearing in JAMA Network Open, showed the absolute mortality gap was small—6.6% versus 6.2%—translating to a number needed to harm of roughly 227 across all trials. Restricting the review to 73 peer-reviewed studies raised the odds ratio to 1.17 and lowered the number needed to harm to 111.
UCLA commentators noted that modern clinical settings differ from trial protocols, citing recent studies like ACORN that found no mortality difference. They suggested the observed risk may stem from cefepime's tight therapeutic margin, where both insufficient and excessive drug exposure could be harmful, making dose optimization a more practical remedy than abandoning the antibiotic.
This finding could prompt clinicians to reassess cefepime dosing protocols, potentially increasing reliance on therapeutic drug monitoring for critically ill patients. Hospitals may adjust empiric antibiotic choices or implement stricter stewardship measures to mitigate the risk. While the absolute mortality difference is tiny, the signal may influence future clinical guidelines and spur prospective trials focused on optimizing exposure, ultimately aiming to preserve cefepime's utility while reducing potential harm.